Your session is about to expire
← Back to Search
Durvalumab + Bevacizumab for Liver Cancer (EMERALD-2 Trial)
EMERALD-2 Trial Summary
This trial is testing if a combination of two drugs, durvalumab and bevacizumab, can help treat patients with hepatocellular carcinoma who are at high risk of the cancer coming back.
EMERALD-2 Trial Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowEMERALD-2 Trial Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2022 Phase 2 trial • 80 Patients • NCT03015129EMERALD-2 Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I have been diagnosed with liver cancer and completed curative therapy.My scans show cancer has spread or is affecting my blood vessels.My organs and bone marrow are working well.I am fully active or can carry out light work.I have not had hepatic encephalopathy in the last year.My liver cancer is a specific type: fibrolamellar, sarcomatoid, or mixed with bile duct cancer.My liver function is slightly impaired.I have received treatment for liver cancer before.My doctor found varices that could bleed through an endoscopy or imaging test.
- Group 1: Arm B
- Group 2: Arm A
- Group 3: Arm C
- Pivotal Trial - The final step before approval, pivotal trials feature drugs that have already shown basic safety & efficacy.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Are there specific inclusion criteria for potential participants of this clinical trial?
"The eligibility requirements for this study are that patients must have carcinoma, hepatocellular and be within the ages of 18 and 150. So far, 908 people have been recruited."
Are there other cases where Durvalumab has been studied before?
"The immunotherapy drug durvalumab was first studied in 2004 at the MSK Basking Ridge facility (Follow Up Only). Since then, there have been 19371 completed studies worldwide. As of now, 701 clinical trials are still recruiting patients; a majority of these trials taking place in Toronto, Canada."
If an elderly person wanted to participate in this trial, would they be allowed?
"Individuals aged 18 to 150 that meet the other requirements set by the research team conducting this trial are eligible to apply. Out of the 4051 trials taking place for people over 65, this is one of 267 trials involving individuals under 18 years old."
Are patients still being signed up for this research project?
"Unfortunately, this study has already closed recruitment. The posting date was April 29th, 2019 and the last update was on November 17th, 2022. However, there are presently 3517 trials actively recruiting participants with carcinoma and 701 studies for Durvalumab that are still looking for volunteers."
What is the total number of participants in this trial?
"Right now, this study is not looking for any more patients. However, it's worth noting that the last update was on November 17th, 2022 and the study was originally posted on April 29th, 2019. If you're interested in other trials, 3517 studies involving carcinoma hepatocellular are actively recruiting participants and 701 studies have open Durvalumab slots."
Has Durvalumab been cleared by the FDA?
"There is both some efficacy data and multiple rounds of safety data, so Durvalumab received a score of 3."
What conditions respond best to Durvalumab?
"Durvalumab is often used to treat recurrent platinum drug resistant primary peritoneal cancer. This immunotherapy medication can also be given to patients with various other conditions including previously untreated, disease, and recurrent non-squamous non-small cell lung cancer."
At how many different medical facilities can patients enroll in this clinical trial?
"At the moment, this trial is recruiting patients from 34 sites. Those in Toronto, Omaha and Ottawa (among other locations) are encouraged to apply to the site closest to them to cut down on travel time if they enroll."
Share this study with friends
Copy Link
Messenger